Disclosures for Albert L. Waldo, M.D.
|
|
- Sabrina Stevens
- 6 years ago
- Views:
Transcription
1 Alternative Anticoagulation Stgies in Atrial Fibrillation: Issues and Answers? Albert L. Waldo, MD The Walter H. Pritchard Professor of Cardiology, Professor of Medicine, and Professor of Biomedical Engineering Case Western Reserve University Disclosures for Albert L. Waldo, M.D. Research Contract: none Consulting: *Biotronik; *St. Jude Medical; *Daiichi Sankyo; **Medtronic Ablation Frontiers; **Astellas Pharma; Biosense Webster; sanofi-aventis; Bristol-Myers Squibb; Portola Pharmaceuticals; Ortho-McNeil-Janssen Pharmaceuticals; Boehringer Ingelheim; CardioInsight; Merck; AtriCure Speaker: sanofi aventis, Harrington-McLaughlin Heart & Vascular Institute HarringtonUniversity Hospitals Case Medical Center Division of Cardiovascular Medicine Cleveland, Ohio Characterizing Atrial Fibrillation Atrial Fibrillation (AF) is the most common sustained arrhythmia in the Western world > 8% of individuals with AF are > 5 years of age At present, just > 5% of individuals with AF are > 75 years of age Soon, 5% of individuals with AF will be > 8 years of age Projected prevalence of AF 5. to million Americans by 5 Lifetime incidence of AF: in individuals > years of age Go AS, et al. JAMA. ;85: Lloyd-Jones DM et al. Circulation. ;:-. Miyasaka Y, et al. Circulation. ;:9-5. Problems With Delayed onset/offset of action Narrow therapeutic range Unpredictable dose response Metabolized by CYP5s (especially C9) Common genetic polymorphisms (especially C9) affect dose requirements Numerous drug drug drug, drug drug food interactions Variable anticoagulant response necessitates coagulation monitoring and dose adjustments Slow reversibility Inconvenience for patient and physician The above most likely contribute to warfarin underuse Modified after Ansell et al. Chest. ;9:S-38S. Hirsh et al. Chest. ;9:S-9S. Preadmission Medications for Patients with Known AF Admitted with Stroke Prevalence of Eligible AF Patients Receiving Therapy is prescribed for only % to 5% of eligible patients with AF, many of whom are considered warfarin-unsuitable Percent patients treated with warfarin *clinical trial steering committee **clinical trial DSMB ATRIA N=,8 NABOR N=95 N=53 Medicare N=7,7 N=,995 N=5,7 ATRIA=Anticoagulation and Risk Factors in Atrial Fibrillation, NABOR=National Anticoagulation Benchmark and Outcomes Report Gladstone DJ et al. Stroke 9;:35-.Go AS et al. Ann Intern Med. 999;3: Waldo AL et al. J Am Coll Cardiol. 5;: Hylek EM et al. Stroke. ;37:75-8..Birman-Deych E et al. Stroke. ;37:7-7. Euro Heart Study7 N=,7 5.Walker AM, Bennett D. Heart Rhythm. 8;5: Williams CJ et al. American College of Cardiology 58th Scientific Session; March 9-3, 9; Orlando, FL. 7.Nieuwlaat R et al. Eur Heart J. ;7:38-3.
2 ACTIVE* W: Cumulative Risk of Stroke * Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events Cumulative hazard s. =.7 (.-.37) P=.. 8.%/yr. Clopidogrel + aspirin..%/yr. Oral anticoagulation therapy Number at risk.5.5 Clopidogrel + aspirin Years 9 9 Oral anticoagulation therapy Primary outcome: Stroke, Systemic Embolus, MI, Vascular Death CL+ = 5.% Risk/Year vs W = 3.93% Risk/Year Connolly S, et al. Lancet. ;37:93-9. Key AF Stroke Risk Factors: CHADS Risk Stratification Scheme C Points Congestive heart failure (recent) H Hypertension A Age 75 years D Diabetes S Prior stroke or TIA TIA = transient ischemic attack Stroke Rate (%) Risk Factor Based on,773 NRAF Pts CHADS Score 5 Gage et al. JAMA. ;85:8-87. (A) Fang M et al. J Am Cardiol 8;5:8-5 Conclusions Fang MC et al. J Am Coll Cardiol 8;5:8-5
3 Conclusions. Current risk stratification schemes used to predict TE in persons with nonvalvular AF have similar discriminatory ability, but the ability is relatively poor.. Until better means of risk stratification are available, a large proportion of patients with AF who would not have developed TE may be exposed to the risks associated with warfarin therapy. 3. Differences across risk schemes could potentially lead to substantial variation in whether or not individual patients are recommended for warfarin therapy.. Need better discriminators to identify for those who will sustain a TE event or who will suffer complications from anticoagulant therapy. Fang MC et al. J Am Coll Cardiol 8;5:8-5. Stroke Risk Stratification in AF CHADS-VASc CHADS Risk Factor Cardiac failure HTN Age 75 y Diabetes Stroke Score Risk Factor Cardiac failure HTN Age 75 y Diabetes Stroke Vascular disease (MI, PAD, aortic atherosclerosis) Age 5-7 y Sex category (female) Score Total Score Risk of Stroke (%) CHADS CHADS-VASc Lip GY, Halperin JL. Am J Med. ;3():8-88. Camm AJ, et al. Eur Heart J. ;3(9):39-9. CHADSVASc Thromboembolic Risk Score Risk Factor / CHADSVASc and Therapy CCVS AF Guidelines Cairns JA, et al. Can J Cardiol ;7:
4 Assessment of Bleeding Risk HAS-BLED Score Hypertension (SBP > mm Hg) Abnormal renal/liver function ( point each) Stroke Bleeding Labile INRs Elderly (age > 5) Drugs or alcohol ( point each) Maximum score Coagulation Cascade Score or or 9 HAS-BLED score of 3 suggests increased bleeding risk and warrants some caution and/or regular review. SBP = systolic blood pressure; INR = international normalized ratio. Initiation Vlla/TF Propagation IXa VllIa acts on II, VII, IX, and X Xa Prothrombin II Va IIa (Thrombin) Fibrin Formation Fibrin Fibrinogen Pisters R et al. Chest ; pub online March 8. DOI:/378/chest.-3. New Oral Anticoagulants X IX New Anticoagulants: Comparison Of RCTs Unmet Clinical Needs in the Treatment of AF - 9% of all strokes are due to AF - Stroke risk can be reduced by 7% with treatment - grossly underused - Use of new, effective, and safe oral agents offers the prospect of simplified (fixed) dosage, rapid onset of action, absence of need for monitoring, and few drug drug and drug food interactions AF Modified after Turpie AG Eur Heart J 8;9:55-5 Dabigatran Etexilate RE-LY: A Non-inferiority Trial Competitive inhibitor of thrombin Atrial fibrillation Risk Factor Absence of contra-indications 95 centers in countries Prodrug - converted completely to active dabigatran Orally active; peak plasma concentration at hours postdose; T ½: 7 hours Extensively metabolized, mainly by CYP3A; proton pump inhibitors reduce absorption; bioavailability is increased by meals Eliminated predominantly by kidneys (8%) Phase data identified mg BID and 5 mg BID as viable doses Stangier J et al. J Clin Pharmacol 5;5:555-53; Liesenfeld KH et al. Br J Clin Pharmacol ;:57-537; Stangier J et al. Br J Clin Pharmacol 7;:9-33 PROBE=Prospective Randomized Open Trial with Blinded Adjudication of Events. R open (INR.-3.) N= Blinded Dabigatran Etexilate mg b.i.d. N= Dabigatran Etexilate 5 mg b.i.d. N= efficacy outcome = stroke or systemic embolism safety outcome = major bleeding Non-inferiority margin. NEJM 3: 39, 9
5 Stroke or Systemic Embolism. Hemorrhagic Stroke.3 <. <. Dabigatran 5 vs. Margin =..75 Dabigatran better..5 HR (95% CI) Dabigatran.5 Dabigatran5 better.5 NEJM 3: 39, 9..5 Years of Follow-up..5 Cardioversion in RE-LY Bleeding D mg D 5mg warfarin 95% CI p 95% CI p Total.%.% 8.% < Major.7 % 3. % 3. % LifeThreatening major. %.5 %.8 % < Gastrointestinal Major. %.5 %. % <. Major bleeding = D 5 mg vs. =. 95% CI =.-.9 P <...5 NEJM 3: 39, 9 D mg vs. =.3 95% CI =.7-.5 P <.. <. Cumulative Hazard Rates Dabigatran vs..3 Superiority p-value. Non-inferiority p-value D mg vs. D 5mg vs. HGB > g/l, transfusion > units, or sympt. bleeding in a critical area or organ Cardioversions (n=,983) were performed in,7 pts: 7 pts on mg bid, 7 pts on 5 mg bid, and pts on warfarin. DC: 53, 55, 553; and pharmacologic: 9,,, respectively. TEE was performed in 5.5%,.%, and 3.3% of D, D5, and warfarin, respectively, with.8%,.%, and.% positive, respectively. Stroke and systemic embolism by 3 days occurred in.77,.3, and. % of pts, respectively. These were not statistically different (with p=. for 5 bid vs warfarin and p=.7 for bid vs warfarin), but the RE-LY trial was not powered for this analysis. There were no differences in major bleeding. There were no differences with vs without TEE This is the largest cardioversion experience published to date! NEJM 3: 39, 9 Nagarakanti et al. Circulation ; 3:3-3 ROCKET AF Trial: Turpie ACG Eur Heart J E Pub Dec.7, 7 mg once daily R N =, 5 mg once daily (creatinine clearance 3-9 ml/min at entry) target INR,.5 (INR range,.-3.) Day Follow-up Nonvalvular AF, history of stroke, TIA, or embolism, or at least of the following: HF, HTN, age 75 years, or diabetes mellitus End of treatment Treatment period -3 months Direct inhibitor of coagulation Factor Xa Well toled Half-life up to hrs in elderly subjects; up to 9 hrs in healthy subjects No direct effect on platelet aggregation Potently inhibits free and clot-associated Factor Xa activity Rapid onset of action (Tmax - hrs) Elimination /3 renal (unchanged); /3 liver metabolism Low propensity for clinically relevant drug-drug interactions Day 3 after last dose In AF patients with a mode to high risk of stroke, does rivaroxaban reduce the risk of major vascular compared with warfarin? study end point: composite of all-cause stroke and non-cns systemic embolism end points: composite of TIA, all-cause death, vascular death, and MI safety end point: composite of major and clinically relevant nonmajor bleeding Randomization completed in June 9; follow-up completed Follow-up: up to years (until 5 primary outcome have been observed) TIA = transient ischemic attack; ROCKET = Randomized, Double-Blind Study Comparing Once Daily Oral With Adjusted-Dose Oral for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation. ROCKET AF Study Investigators. Am Heart J. ;59(3):3-37.e. 5
6 Primary Efficacy Outcome Stroke and non-cns Embolism Rocket-AF: Baseline Demographics (N=79) Prior VKA Use (%) 3 Congestive Heart Failure (%) 3 Hypertension (%) 9 9 Diabetes Mellitus (%) 39 Prior Stroke/TIA/Embolism (%) Prior Myocardial Infarction (%) 7 8 CHADS Score (mean) (%) 3 (%) (%) 5 (%) (%) Cumulative event (%) (N=78) 5 Event Rate HR (95% CI):.79 (.,.9) P-value Non-Inferiority: <. No. at risk: Mahaffey KW et al. AHA presentation Chicago /5/ Event Rates are per patient-years Based on Protocol Compliant on Treatment Population Stroke and Non-CNS Embolism On Treatment * Event Rate Event Rate.7. N=,3 ITT N=,7 ROCKET-AF Outcome HR (95% CI) P-value.5.79 (.5,.95) (.7,.3).7 TTR 57.8% better Average CHADS score 3.7 * is not FDA-approved. Event s are per patient-years. Based on safety on treatment or ITT thru site notification populations. ITT = intention to treat. Califf RM. Presented at: American Heart Association Scientific Sessions; November 5, ; Chicago, IL. (n=78) (n=79) Hazard ratio (95% CI) p (..9) <..5 Primary end point, noninferiority Primary end point, ontreatment superiority (.5.95) Primary end point, intention-to-treat superiority...88 (.7.3).7 Vascular death, stroke, embolism ).3 Hemorrhagic stroke...59 (.37.93) Ischemic stroke.3..9 (.75.7) Unknown stroke...5 (.5.7) Mahaffey KW et al. AHA presentation Chicago /5/ ROCKET AF: Key Secondary Efficacy Outcomes Event Rate Event Rate HR (95% CI) P-value (.8,.5).5 Stroke Type Hemorrhagic Ischemic Unknown type (.38,.89).99 (.8,..5 (.55,.) Non-CNS Embolism...7 (.,.3.38 MI...9 (.7,.). All Cause Mortality Vascular Nonvascular Unknown cause (.8,.3).9 (.8,.8).9 (.75,.8).8 (.57,.) Event s are per patient-years. Based on ITT population. Days from Randomization ROCKET AF: Primary Efficacy Outcome Vascular Death, Stroke, Embolism. 3 Based on Intention-to-Treat Population better.7 ROCKET-AF Outcome (n=78) (n=79) Hazard ratio (95% CI) p Major and nonmajor bleeding Major bleeding (.9.) (.9.).57 > g/dl hemoglobin.77.. (.3.) (..55) (.53.9) (.3.79) (.7.9).9 drop Transfusion Critical organ bleeding Bleeding causing death Intracranial hemorrhage Mahaffey KW et al. AHA presentation Chicago /5/ Mahaffey KW et al. AHA presentation Chicago /5/
7 Rocket-AF: Summary CHADS Scores: RE-LY and ROCKET-AF Efficacy: RE-LY (a) was non-inferior to warfarin for prevention of stroke and non-cns embolism. was superior to warfarin while patients were taking study drug. By intention-to-treat, rivaroxaban was non-inferior to warfarin but did not achieve superiority. (b) CHADS Score Dabigatran mg Dabigatran 5 mg Mean % 3.%.% 3.7% 35.% 37.% 3% 3% 3-3.7% 3.% 3.% 87% 87% Safety: Similar s of bleeding and adverse. ROCKET-AF Less ICH and fatal bleeding with rivaroxaban. Conclusion: a) Connolly SJ et al. N Engl J Med 9;3:39-5 is a proven alternative to warfarin for mode or high risk patients with AF. b) Data presented by Mahaffey KW. AHA; ; Chicago. ROCKET AF Compared with RE-LY ROCKET AF ROCKET AF Compared with RE-LY RE-LY ROCKET AF RE-LY 58% 7% N,7 8,3 VKA naive 37% 5% Design Randomized, double-blind, double-dummy study PROBE design Treatment Dabigatran CHADS (mean) 3.7. dose (with dose adaptation for mode renal impairment) doses Previous TIA/CVA 55% % Regimen Once daily Twice daily Primary outcome HR.79. (5 dose) Primary outcome Efficacy: Composite of all-cause stroke and non-cns systemic embolism Efficacy: Incidence of stroke (including hemorrhagic) and systemic embolism Hemorrhagic CVA.. (5 dose) Safety: Composite of major and clinically relevant nonmajor bleeding Secondary outcome Each category of bleeding, and adverse Composite of TIA, all-cause death, vascular death, and MI TTR (median) Safety: Major bleeding Incidence of stroke (including hemorrhagic), systemic embolism, all death, pulmonary embolism, MI, TIA, vascular deaths (including deaths from bleeding), and hospitalizations ROCKET AF Investigators. Am Heart J. ;59:3-7.e. Connolly SJ, et al. N Engl J Med. 9;3:39-5. Ischemic CVA: HR (5 dose) Major Bleeding 3.% 3.3% (5 dose) ROCKET AF Study Investigators. Am Heart J. ;59:3-37.e. Connolly SJ, et al. N Engl J Med. 9;3:39-5. ARISTOTLE Trial: Oral, direct, selective factor Xa inhibitor N No formation of reactive intermediates No organ toxicity or liver function test abnormalities in chronic toxicology studies O N Double-blind N O No food effect Balanced elimination (~5% renal) T/: ~ hours R 5 mg twice daily.5 mg twice daily in selected patients* Low likelihood of drug interactions or QTc prolongation Good oral bioavailability E NH N O INR,.-3. AF or atrial flutter 8, randomized O Produces concentration-dependent anticoagulation Is apixaban noninferior to standard therapy (warfarin) in preventing stroke and systemic embolism in mode- to high-risk (stroke, at least risk factor) AF/AFL patients? efficacy end point: confirmed ischemic or hemorrhagic stroke, or systemic embolism efficacy end points: composite of confirmed ischemic or hemorrhagic stroke, systemic embolism, and all-cause death safety end point: time to first occurrence of confirmed major bleeding Treatment period: up to years (until 8 primary outcome have been observed >9% power to demonst noninferiority) Stratified by warfarin-naïve status *At least of the following: age 8 years, weight kg, or serum creatinine.5 mg/dl. ARISTOTLE = for reduction in stroke and other thromboembolic in atrial fibrillation. He K, et al. Blood. ;8:9. Lassen MR. Blood. ;8:57 Lopes RD, et al. Am Heart J. ;59(3):
8 AVEOES: Stroke or Systemic Embolic Event AVEOES Trial Unsuitable for warfarin therapy 8-3 mg daily up to 3 mo/end of study N= 5 R 5 mg twice daily.5 mg twice daily in selected patients* up to 3 mo/end of study Is apixaban more effective than in preventing stroke and systemic embolism in mode to high-risk (stroke, at least risk factor) AF patients? efficacy end point: confirmed ischemic or hemorrhagic stroke or systemic embolism study end points: as above, including MI or vascular death safety end point: major bleeding Study period: until primary outcome have been observed In June, the study was stopped early because a predefined interim analysis revealed clear Number at Risk AVEOES = Versus to Reduce the Risk of Stroke. Eikelboom JW, et al. Am Heart J. ;59(3): e. Connolly SJ, et al. Presented at: European Society of Cardiology; ; Stockholm, Sweden Randomized Age (mean and SD) 7 ± yrs 7 ± yrs Male (59%) 5 (%) CHADS score (mean and SD) ±. 5 (3%) (37%) 7 (7%).±. 7 (37%) 959 (3%) 8 (9%) Prior stroke/tia 389 (%) 375 (%) Diabetes 537 (9%) 558 (%) Hypertension (87%) (8%) CHF 3 (%) 5 (38%) Baseline (7%) 7 (7%) Prior VKA use and discontinued 83 (39%) 89 (39%) Outcome Stroke, MI, SEE or Vascular Death.3 MI Vascular Death 7 8 Months Major 7 Clinically Relevant Nonmajor Minor vs. 95% CI P Fatal Intra-cranial Connolly SJ, et al. N Engl J Med. Feb. [Epub ahead of print] AVEOES: Bleeding Events vs. 95% CI P < CV Hospitalization Total Death Connolly SJ, et al. N Engl J Med. Feb. [Epub ahead of print] Outcome AVEOES: and Other Efficacy Outcomes 7 7 AVEOES: Bleeding Events Connolly SJ, et al. N Engl J Med. Feb. [Epub ahead of print] 3 Connolly SJ, et al. N Engl J Med. Feb. [Epub ahead of print] Baseline Characteristics Characteristic evidence of a clinically important reduction in stroke and systemic embolism *At least of: age 8 years, weight kg, or serum creatinine.5 mg/dl..3 Cumulative Risk Relative Risk =. 95% CI,.33-. P<..5 Double-blind.. E Outcome Major 7. Clinically Relevant Nonmajor Minor 55 Fatal Intra-cranial vs. 95% CI P Connolly SJ, et al. N Engl J Med. Feb. [Epub ahead of print] 8
9 Characteristics of Edoxaban...5 Relative Risk =. 95% CI, P=.5.5. Cumulative Risk AVEOES: Major Bleeding 3 Number at Risk Months Connolly SJ, et al. N Engl J Med. Feb. [Epub ahead of print]. Potent and specific inhibitor of factor Xa Bioavailability over 5% Rapidly absorbed - Cmax - hours Half-life of 8 to hours Multiple pathways of excretion: 3% renal and 5% hepatic Linear PK, providing a predictable and consistent exposure Exposure to edoxaban increases with renal dysfunction and low body wt (< kg) It is a subst for the efflux transporter p-glycoprotein (P-gp) reduced dosage of edoxaban may be needed when coadministered with strong P-gp inhibitors (e.g., verapamil, quinidine) Once daily regimens associated with less bleeding than twice daily regimens Weitz JI. Presented at the 5 th ASH meeting San Francisco, CA; Ruff CT et al. Am Heart J ;:35- ENGAGE AF TIMI 8: Edoxaban Summary. Once-daily edoxaban dosing regimens are associated with less bleeding than twice-daily regimens INR,.-3. AF >, patients E 3 treatment arms R Double-blind Edoxaban. Edoxaban, at 3 or mg OD, appears to have a safety profile similar to that of warfarin (target INR of to 3) mg vs 3 mg qd Weitz JI. Presented at the 5 th American Society for Hematology meeting San Francisco, CA Is edoxaban noninferior to standard therapy (warfarin) in preventing stroke and systemic embolism in modeto-high-risk (CHADS score ) AF patients? efficacy end point: composite primary end point of stroke and systemic embolic efficacy end points: composite clinical outcome of stroke, systemic embolic, and all-cause mortality; also major bleeding Treatment period: up to years ENGAGE AF TIMI = Global Study to Assess the Safety and Effectiveness of DU-7b vs Standard Practice of Dosing With in Patients with Atrial Fibrillation. ClinicalTrials.gov identifier NCT7839. Clinical Challenges With New Oral Anticoagulants No validated tests to measure anticoagulation effect No established therapeutic range No antidote for most agents Assessment of compliance more difficult than with vitamin K antagonists Potential for unknown long-term adverse Balancing cost against efficacy Lack of head-to-head studies comparing new agents Sobieraj-Teague M, et al. Semin Thromb Hemost. 9;35:55-5. Baseline Characteristics of the AF Ablation Treated Patients Measure AF type Paroxysmal Persistent Permanent CHADS > Total population, % (n=3355) Off OAC therapy, % (n=9) On OAC therapy, % (n=3) p 8 5 <. < <. <. <. Themistoclakis S, et al. J Am Coll Cardiol ; 55:
10 PROTECT AF Trial: WATCHMAN LAA Closure Device in situ Themistoclakis S, et al. J Am Coll Cardiol ; 55:
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationTherapeutic Advances for the Management of Thrombosis: Navigating the New Paradigm. Formulary and Contract Manager SelectHealth
Therapeutic Advances for the Management of Thrombosis: Navigating the New Paradigm Jeffrey D Dunn PharmD MBA Jeffrey D. Dunn, PharmD, MBA Formulary and Contract Manager SelectHealth Faculty Disclosure
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationKenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationArrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies
Arrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies Samuel Asirvatham, MD & Ivan Mendoza, MD Saturday, June 24, 2017 11:15 a.m. to 12 p.m. Disclosures Relevant financial relationship(s)
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationModeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD
Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD Mount Sinai School of Medicine New York, NY Session II. Weighing the Risks and Benefits
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationNew Strategies in the World of Anticoagulant Therapy. October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center
New Strategies in the World of Anticoagulant Therapy October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center Presenter Disclosure Information Elaine M. Hylek, MD, MPH Research: NIH/NINDS,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationStroke prevention, Clinical trials
Received: 13 May 2016 Revised: 8 August 2016 Accepted: 18 August 2016 DOI 10.1002/clc.22596 REVIEWS Special considerations for therapeutic choice of non vitamin K antagonist oral anticoagulants for Japanese
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationStroke. 2012;43: ; originally published online August 2, 2012; doi: /STR.0b013e a
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation : A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationANTITHROMBOTIC THERAPY IN CARDIOLOGY. Sokratis Pastromas, MD
HOSPITAL CHRONICLES 2012, VOLUME 7, SUPPLEMENT 1: 54 60 ANTITHROMBOTIC THERAPY IN CARDIOLOGY Newer Anticoagulants for Atrial Fibrillation: the Role of Dabigatran, Rivaroxaban, Apixaban and Edoxaban / RELY,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationIs Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Apixaban Effective for the Prevention
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationManaging Atrial Fibrillation in the Heart Failure Patient
Managing Atrial Fibrillation in the Heart Failure Patient Jonathan S. Steinberg, MD Professor of Medicine (adj) University of Rochester School of Medicine & Dentistry Director, Arrhythmia Institute Valley
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More information